Therapeutic management of upper urinary tract stone disease in 172 subjects.
Three hundred one patients with recurrent renal calculi were studied: 129 patients received no treatment, and 172 received either bendrofluazide (90) or allopurinol (82). The renal stone recurrence rate was assessed over a five-year period, and it was noted that the incidence of recurrence was significantly lower in patients receiving either bendrofluazide or allopurinol. In male patients there was no difference in recurrence rates in those receiving the different drugs, but female patients receiving allopurinol had a significantly lower five-year recurrence rate when compared with those receiving bendrofluazide.
Scott
R
R
Department of Urology, Royal Infirmary, Glasgow, Scotland.
Lewi
H
H
D000284:Administration, Oral; D000493:Allopurinol / Q000008:administration & dosage / Q000627:therapeutic use*; D001539:Bendroflumethiazide / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D011446:Prospective Studies; D011897:Random Allocation; D012008:Recurrence; D012737:Sex Factors
D001539:Bendroflumethiazide; D000493:Allopurinol